The Opioid Crisis Was Never Only Rural and White

The dominant account of America’s opioid crisis is familiar: pharmaceutical companies flooded rural and suburban communities with prescription painkillers; physicians prescribed too freely; and working-class white Americans, already battered by deindustrialization and economic decline, became the principal victims of what researchers famously termed “deaths of despair.”

That account contains important truths, but its dominance obscured a larger reality. The crisis was never singular, and it was never confined to rural or white America. It has always been a patchwork of sub-epidemics shaped by drug type, geography, race, and public policy.

Narratives matter because they dictate policy. The Centers for Disease Control and Prevention’s “three-wave” framework—prescription opioids, followed by heroin, followed by illicit fentanyl—encouraged policymakers to understand the crisis primarily as a drug-supply problem. This led to an aggressive push for prescription limits, monitoring programs, and enforcement.

Yet even as prescribing fell substantially, overdose mortality continued to rise, driven by illegally manufactured fentanyl and polysubstance use. The policy response remained trapped in the first chapter while the human toll shifted elsewhere.

That fixation carried a racial and geographic bias. When crack cocaine devastated Black communities in the 1980s, the national response emphasized crime, mandatory sentencing, and incarceration. Later, when prescription opioids spread through white communities, drug use was framed through a compassionate public health lens that recognized injured workers and victims of corporate misconduct. White opioid users were granted a degree of social innocence rarely afforded to Black drug users.

However, when illicit fentanyl transformed the drug supply, these biased narratives failed to protect anyone, while the underlying double standard left urban minority communities dangerously exposed.

The media system that made rural white suffering emblematic was slower to recognize fentanyl’s devastating toll on racially segregated urban communities. Federal data reveal the resulting blind spot. From 2019 to 2020, drug overdose death rates increased by 44 percent among Black Americans and 39 percent among American Indian and Alaska Native people, compared with 22 percent among white Americans.

The disparity persisted even as national overdose mortality began to decline. From 2022 to 2023, the overdose death rate among white Americans fell from 35.6 to 33.1 deaths per 100,000, while the Black rate rose from 47.5 to 48.9. American Indian and Alaska Native communities experienced the highest mortality rate of all—65 deaths per 100,000, nearly twice the white rate and one-third higher than the Black rate. 

These disparities cannot be explained by individual behavior alone. They reflect structural inequalities: residential segregation, underinvested healthcare infrastructure, medical mistrust, and unequal access to office-based buprenorphine treatment for opioid use disorder. Fentanyl did not enter a socially neutral environment; it entered communities whose vulnerabilities were built over generations.

Geography further complicates the story. County-level research shows that the opioid crisis is not a single, uniform epidemic but a collection of overlapping epidemics involving different drugs, populations, and local conditions.

Prescription-opioid mortality was concentrated disproportionately in less-populated, predominantly white counties characterized by economic decline, manual-labor industries, occupational injuries, and high rates of disability. Heroin and multi-opioid mortality were more common in urban and racially diverse counties. Yet even the label “urban” can conceal important disparities: a metropolitan county may appear prosperous overall while overdose deaths are concentrated among a relatively small Black population living in deeply disadvantaged and segregated neighborhoods.

Rural communities face a different combination of risks, including physically demanding work, chronic pain, geographic isolation, and limited access to healthcare and addiction treatment. Data from the University of Washington Rural Health Research Center highlight this divide: before the federal buprenorphine-waiver requirement was eliminated in 2023, 30.1 percent of rural counties had no waivered clinician in as of 2022, compared with 10.4 percent of urban counties, leaving rural areas with far fewer authorized providers per capita. 

Conversely, urban residents face structural barriers rather than distance. The physical presence of a hospital does not guarantee equitable care. Black patients encounter insurance and transportation barriers, shortages of culturally responsive clinicians, mistrust rooted in medical discrimination, and treatment pathways stratified by race and class. Studies show that office-based buprenorphine has predominantly served white, middle-class patients, while heavily regulated and stigmatized methadone clinics are concentrated in lower-income minority neighborhoods.

Despite these differences, rural and urban communities share many upstream drivers: economic insecurity, trauma, frayed social connections, and inadequate behavioral health care. As social risk frameworks demonstrate, these forces do not operate in isolation. Four connected domains—economic conditions, social connections, physical environment, and public policy—interlock to shape overdose risk. Job loss connects to housing instability, policing dictates local drug markets, and geographic isolation amplifies provider shortages. Overdose risk does not originate solely within individuals; it is organized by the environment around them.

Effective policy requires abandoning a uniform national approach. Rural communities need mobile treatment units, expanded telehealth, reliable transportation, more access to medications for opioid use disorder, and harm-reduction services adapted to geographic isolation.

Urban communities require targeted outreach in historically underserved Black neighborhoods, low-threshold treatment, stable housing supports, and fewer criminal-justice barriers. Native populations require a commitment to culturally responsive care. Across all settings, health systems should disaggregate data by race, ethnicity, drug type, and location to audit who is receiving care and who is being left behind.

The opioid crisis was never only rural and white. Rural white communities experienced genuine devastation, but their story was mistaken for the whole. Policies that recognize the overdose crisis as a complex patchwork of sub-epidemics—each shaped by distinct drugs, populations, places, and structural conditions—will be more successful in preventing drug-related harm and saving lives.

Lynn Webster (he/him), M.D., is an addiction and pain specialist. He is a Senior Fellow at the Center for U.S. Policy and co-author of Deconstructing Toxic Narratives: Data, Disparities and a New Path Forward in the Opioid Crisis (Springer Nature 2026). Learn more at lynnwebstermd.com.